Another study found that the AKT pathway is an important regulatory pathway for ARL4C expression in lung cancer cells, and the authors showed that the chemotherapeutic drug hydroxycamptothecin (HCPT0) could be used to treat the lung adenocarcinoma by targeting the expression of ARL4C [36]. Here, AKT1 is linked to lung cancer.